Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma

• Date :
• 1    
  0

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL

• Date :
• 1    
  0

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell

• Date :
• 1    
  0

CLL14: Venetoclax plus obinutuzumab in untreated CLL

• Date :
• 0    
  0

Interim analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML

• Date :
• 0    
  0

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control

• Date :
• 0    
  0

Carfilzomib-lenalidomide-dexamethasone in the management

• Date :
• 0    
  0

A phase II study of blinatumomab for the treatment of MRD-positive B-cell acute lymphoblastic

• Date :
• 0    
  0

Interim results of a phase II study of blinatumomab plus ponatinib for Philadelphia

• Date :
• 0    
  0

Fixed-duration ibrutinib and venetoclax for first-line CLL

• Date :
• 0    
  0

Isatuximab, carfilzomib, lenalidomide and dexamethasone (Isa-KRd) in front-line treatment

• Date :
• 0    
  0

Once weekly selinexor, carfilzomib, and dexamethasone (XKD)in carfilzomib non-refractory

• Date :
• 0    
  0

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone

• Date :
• 0    
  0

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R b-cell non-Hodgkin’s lymphoma

• Date :
• 0    
  0

Latest developments in the use of immunotherapy for relapsed or refractory multiple myeloma

• Date :
• 0    
  0

9ème Journée Nationale Maladies Rares Immuno-Hématologiques - MaRIH 2023

• Date :
• 3380    
  6

International Society on Thrombosis and Haemostasis congress - ISTH 2023

• Date :
• 4963    
  0

The European Hematology Association - EHA 2023

• Date :
• 8092    
  0

MDS - 17th International Congress on Myelodysplastic Syndromes

• Date :
• 12637    
  0

43e congrès annuel de la Société Française d’Hématologie - SFH 2023

• Date :
• 9346    
  7